SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Ipca Laboratories gains on receiving nod for merger of Tonira Pharma with itself

Ipca Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524494 | NSE: IPCALAB

19 Sep 2011 Evaluate

Ipca Laboratories is currently trading at Rs. 282.00, up by 5.00 points or 1.81% from its previous closing of Rs. 277.00 on the BSE.

The scrip opened at Rs. 283.10 and has touched a high and low of Rs. 283.10 and Rs. 278.10 respectively.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 351.00 on 14-Jun-2011 and a 52 week low of Rs. 255.10 on 10-Mar-2011.

Last one week high and low of the scrip stood at Rs. 314.45 and Rs. 271.00 respectively. The current market cap of the company is Rs. 3,544.00 crore.

The promoters holding in the company stood at 46.05% while Institutions and Non-Institutions held 32.28% and 21.67% respectively.

Ipca Laboratories has received an approval for amalgamation of Tonira Pharma with the company with effect from April 01, 2011 being the appointed date through a scheme of amalgamation. The board at its meeting held on September 17, 2011 has considered and approved the same. However, the proposed scheme of amalgamation will be subject to all necessary permissions and approvals, as may be required.

Further, the scheme envisages an exchange ratio of six equity shares of Rs 2 each fully paid-up of Ipca Laboratories for every one hundred equity shares of Rs 10 each fully paid-up of Tonira Pharma. The exchange ratio is based on the joint valuation made by Natvarlal Vepari & Company, Chartered Accountants and G. M. Kapadia & Company, Chartered Accountants.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Tonira Pharma is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates. Tonira undertakes contract synthesis both on exclusive and non-exclusive basis. The company has the capability to provide contract research and manufacturing services to its customers.

Ipca Laboratories Share Price

1493.80 16.55 (1.12%)

22-Apr-2026 15:40 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1669.50
Dr. Reddys Lab	1216.60
Cipla	1239.65
Zydus Lifesciences	928.00
Lupin	2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Ipca Laboratories gains on receiving nod for merger of Tonira Pharma with itself

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.